Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says

Harrow (NASDAQ:HROW) had its price target boosted by HC Wainwright from $69.00 to $70.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 81.35% from the company’s current price.

A number of other equities research analysts also recently issued reports on HROW. LADENBURG THALM/SH SH upped their price objective on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Zacks Research lowered Harrow from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $94.00 price objective on shares of Harrow in a research note on Tuesday, November 11th. William Blair reiterated an “outperform” rating on shares of Harrow in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Harrow currently has an average rating of “Moderate Buy” and a consensus target price of $71.14.

Harrow Trading Down 28.0%

HROW stock opened at $38.60 on Wednesday. The firm has a fifty day moving average price of $48.41 and a 200 day moving average price of $43.79. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The firm has a market cap of $1.43 billion, a PE ratio of -227.05 and a beta of 0.05. The company has a debt-to-equity ratio of 5.21, a quick ratio of 2.52 and a current ratio of 2.72.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.23). Harrow had a negative net margin of 1.89% and a positive return on equity of 36.76%. The business had revenue of $89.09 million for the quarter, compared to the consensus estimate of $88.42 million. Sell-side analysts anticipate that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harrow

Large investors have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in Harrow by 102.5% during the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock worth $261,000 after buying an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares during the last quarter. Strs Ohio bought a new stake in Harrow during the first quarter valued at about $149,000. Teacher Retirement System of Texas grew its stake in Harrow by 4.1% in the second quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock valued at $259,000 after purchasing an additional 332 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in Harrow by 68.0% in the second quarter. Los Angeles Capital Management LLC now owns 28,779 shares of the company’s stock worth $879,000 after purchasing an additional 11,650 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow News Summary

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Record revenue, margin progress and cash generation: Harrow reported Q4 revenue of $89.1M (33% YoY) and full‑year 2025 revenue of $272.3M (36% YoY); adjusted EBITDA rose to $61.9M for 2025 and operating cash flow turned positive ($43.9M). These fundamentals support longer‑term growth prospects. Q4 Results
• Positive Sentiment: Clinical progress: the FDA cleared an IND to support a planned Phase 3 trial for TRIESENCE to expand its label for post‑cataract inflammation and pain — a successful program could add a higher‑value indication. Phase 3 IND
• Positive Sentiment: Investor outreach: management will present at Leerink Partner’s Global Healthcare Conference (Mar 10), offering an opportunity to clarify strategy and guidance execution. Conference Presentation
• Neutral Sentiment: Full Q4 earnings call and slide deck are available for deeper inspection of unit trends (product mix, ImprimisRx shift toward higher‑margin items) and management commentary. Investors should review the transcript/slides for details. Earnings Call Transcript
• Negative Sentiment: EPS miss and mixed metrics: Harrow’s reported EPS missed consensus (company reported an EPS shortfall vs. expectations) even as revenue broadly met estimates — the profit miss is weighing on sentiment. Earnings Miss
• Negative Sentiment: FY2026 revenue guidance of $350M–$365M and Adjusted EBITDA $80M–$100M came in well below the consensus (~$394M), signaling growth that management expects to be back‑loaded; markets view the guidance shortfall as the primary near‑term negative driver. Guidance
• Negative Sentiment: Analyst downgrade and leverage concerns: a Seeking Alpha note downgraded HROW to “Sell,” highlighting persistent low margins, high leverage and rising interest expense that could constrain cash flow if growth is costly — contributing to downside pressure. Analyst Downgrade

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.